<DOC>
	<DOC>NCT02500329</DOC>
	<brief_summary>This is a phase 4, single center, randomized, open-labeled study. The primary objective of the study is to compare effect of gemigliptin and acarbose on endothelial function. Subjects are randomized to gemigliptin or acarbose group and maintained intial treatment for 4 weeks.</brief_summary>
	<brief_title>Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM Patients</brief_title>
	<detailed_description />
	<mesh_term>Acarbose</mesh_term>
	<criteria>age: 2080yrs patients with type 2 diabetes (duration of diabetes &gt;=3 months) HbA1c :&gt;7.0 and &lt;=9.0% on metformin monotherapy no changes on medications during recent 3 months. patients with type 1 diabetes history of medications including Î±glucosidase inhibitor, glinide, GLP1 analogue, other DPP4 Inhibitors, or insulin during recent 3 months. history of acute diabetic complication, acute coronary events, or coronary bypass surgery/interventions during recent 6 months. patients with congestive heart failure (NYHA II~IV) or clinically significant ventricular arrhythmia serum ALT or AST&gt; 2.5 x upper normal range serum direct bilirubin &gt; 1.3 x upper normal range serum creatinine &gt; (men) 1.5 mg/dL, (women)&gt;1.4 mg/dL smoker pregnant women, or breastfeeding women medication with acetylsalicylic acid or vitamin K antagonist</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>